Enpp/Carbonic anhydrase-IN-1

Name: Enpp/Carbonic anhydrase-IN-1
Brand: MedChemExpress
SKU: HY-151916
Rating: 4.5 (1 reviews)

Cat. No.: HY-151916 Purity: 99.57%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Enpp/Carbonic anhydrase-IN-1 (compound 1e) is a potent Enpp and carbonic anhydrase inhibitor with IC₅₀s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonic anhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonic anhydrase-IN-1 induces Apoptosis.

For research use only. We do not sell to patients.

Enpp/Carbonic anhydrase-IN-1 Chemical Structure

CAS No. : 2883495-35-8

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Carbonic Anhydrase Isoform Specific Products:

View All Isoforms

CA CA I CA Ⅱ CA IX CA XII CA VII CA VI CA VA CA VB CA XIII CA XIV

View All Phosphodiesterase (PDE) Isoform Specific Products:

View All Isoforms

PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

CA Ⅱ

0.88 μM (IC₅₀)

CA IX

1.02 μM (IC₅₀)

NPP1

1.36 μM (IC₅₀)

NPP2

1.35 μM (IC₅₀)

NPP3

3.00 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	3.8 μM Compound: 1e	Cytotoxicity against human 786-0 cells assessed as cell growth inhibition Cytotoxicity against human 786-0 cells assessed as cell growth inhibition	[PMID: 36470105]
A498	IC₅₀	2.04 μM Compound: 1e	Cytotoxicity against human A498 cells assessed as cell growth inhibition Cytotoxicity against human A498 cells assessed as cell growth inhibition	[PMID: 36470105]
A549	IC₅₀	6.9 μM Compound: 1e	Cytotoxicity against human A549 cells assessed as cell growth inhibition Cytotoxicity against human A549 cells assessed as cell growth inhibition	[PMID: 36470105]
ACHN	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human ACHN cells assessed as cell growth inhibition Cytotoxicity against human ACHN cells assessed as cell growth inhibition	[PMID: 36470105]
BT-549	IC₅₀	3.24 μM Compound: 1e	Cytotoxicity against human BT-549 cells assessed as cell growth inhibition Cytotoxicity against human BT-549 cells assessed as cell growth inhibition	[PMID: 36470105]
CAKI-1	IC₅₀	7.08 μM Compound: 1e	Cytotoxicity against human CAKI-1 cells assessed as cell growth inhibition Cytotoxicity against human CAKI-1 cells assessed as cell growth inhibition	[PMID: 36470105]
COLO 205	IC₅₀	0.87 μM Compound: 1e	Cytotoxicity against human COLO 205 cells assessed as cell growth inhibition Cytotoxicity against human COLO 205 cells assessed as cell growth inhibition	[PMID: 36470105]
DU-145	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human DU-145 cells assessed as cell growth inhibition Cytotoxicity against human DU-145 cells assessed as cell growth inhibition	[PMID: 36470105]
HCC 2998	IC₅₀	5.48 μM Compound: 1e	Cytotoxicity against human HCC 2998 cells assessed as cell growth inhibition Cytotoxicity against human HCC 2998 cells assessed as cell growth inhibition	[PMID: 36470105]
HCT-116	IC₅₀	2.5 μM Compound: 1e	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition	[PMID: 36470105]
HCT-15	IC₅₀	1 μM Compound: 1e	Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition	[PMID: 36470105]
HL-60(TB)	IC₅₀	8.39 μM Compound: 1e	Cytotoxicity against human HL-60(TB) cells assessed as cell growth inhibition Cytotoxicity against human HL-60(TB) cells assessed as cell growth inhibition	[PMID: 36470105]
HOP-62	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human HOP-62 cells assessed as cell growth inhibition Cytotoxicity against human HOP-62 cells assessed as cell growth inhibition	[PMID: 36470105]
HOP-92	IC₅₀	1.87 μM Compound: 1e	Cytotoxicity against human HOP-92 cells assessed as cell growth inhibition Cytotoxicity against human HOP-92 cells assessed as cell growth inhibition	[PMID: 36470105]
HT-29	IC₅₀	0.4 μM Compound: 1e	Cytotoxicity against human HT-29 cells assessed as cell growth inhibition Cytotoxicity against human HT-29 cells assessed as cell growth inhibition	[PMID: 36470105]
Hs-578T	IC₅₀	7.29 μM Compound: 1e	Cytotoxicity against human Hs-578T cells assessed as cell growth inhibition Cytotoxicity against human Hs-578T cells assessed as cell growth inhibition	[PMID: 36470105]
IGROV-1	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human IGROV-1 cells assessed as cell growth inhibition Cytotoxicity against human IGROV-1 cells assessed as cell growth inhibition	[PMID: 36470105]
K562	IC₅₀	0.32 μM Compound: 1e	Cytotoxicity against human K562 cells assessed as cell growth inhibition Cytotoxicity against human K562 cells assessed as cell growth inhibition	[PMID: 36470105]
KM12	IC₅₀	2.1 μM Compound: 1e	Cytotoxicity against human KM12 cells assessed as cell growth inhibition Cytotoxicity against human KM12 cells assessed as cell growth inhibition	[PMID: 36470105]
LOX IMVI	IC₅₀	4.38 μM Compound: 1e	Cytotoxicity against human LOX IMVI cells assessed as cell growth inhibition Cytotoxicity against human LOX IMVI cells assessed as cell growth inhibition	[PMID: 36470105]
M14	IC₅₀	7.2 μM Compound: 1e	Cytotoxicity against human M14 cells assessed as cell growth inhibition Cytotoxicity against human M14 cells assessed as cell growth inhibition	[PMID: 36470105]
MCF7	IC₅₀	3.26 μM Compound: 1e	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition Cytotoxicity against human MCF7 cells assessed as cell growth inhibition	[PMID: 36470105]
MDA-MB-231	IC₅₀	3.79 μM Compound: 1e	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition	[PMID: 36470105]
MDA-MB-435	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human MDA-MB-435 cells assessed as cell growth inhibition Cytotoxicity against human MDA-MB-435 cells assessed as cell growth inhibition	[PMID: 36470105]
MDA-MB-468	IC₅₀	3.8 μM Compound: 1e	Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition	[PMID: 36470105]
Malme-3M	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human Malme-3M cells assessed as cell growth inhibition Cytotoxicity against human Malme-3M cells assessed as cell growth inhibition	[PMID: 36470105]
NCI-H226	IC₅₀	27.7 μM Compound: 1e	Cytotoxicity against human NCI-H226 cells assessed as cell growth inhibition Cytotoxicity against human NCI-H226 cells assessed as cell growth inhibition	[PMID: 36470105]
NCI-H23	IC₅₀	6.68 μM Compound: 1e	Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition	[PMID: 36470105]
NCI-H322M	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human NCI-H322M cells assessed as cell growth inhibition Cytotoxicity against human NCI-H322M cells assessed as cell growth inhibition	[PMID: 36470105]
NCI-H460	IC₅₀	6.1 μM Compound: 1e	Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition	[PMID: 36470105]
NCI-H522	IC₅₀	4.36 μM Compound: 1e	Cytotoxicity against human NCI-H522 cells assessed as cell growth inhibition Cytotoxicity against human NCI-H522 cells assessed as cell growth inhibition	[PMID: 36470105]
NCI/ADR-RES	IC₅₀	5.75 μM Compound: 1e	Cytotoxicity against human NCI/ADR-RES cells assessed as cell growth inhibition Cytotoxicity against human NCI/ADR-RES cells assessed as cell growth inhibition	[PMID: 36470105]
OVCAR-4	IC₅₀	8.38 μM Compound: 1e	Cytotoxicity against human OVCAR-4 cells assessed as cell growth inhibition Cytotoxicity against human OVCAR-4 cells assessed as cell growth inhibition	[PMID: 36470105]
OVCAR-5	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human OVCAR-5 cells assessed as cell growth inhibition Cytotoxicity against human OVCAR-5 cells assessed as cell growth inhibition	[PMID: 36470105]
OVCAR-8	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human OVCAR-8 cells assessed as cell growth inhibition Cytotoxicity against human OVCAR-8 cells assessed as cell growth inhibition	[PMID: 36470105]
PC-3	IC₅₀	2.9 μM Compound: 1e	Cytotoxicity against human PC-3 cells assessed as cell growth inhibition Cytotoxicity against human PC-3 cells assessed as cell growth inhibition	[PMID: 36470105]
RPMI-8226	IC₅₀	0.4 μM Compound: 1e	Cytotoxicity against human RPMI-8226 cells assessed as cell growth inhibition Cytotoxicity against human RPMI-8226 cells assessed as cell growth inhibition	[PMID: 36470105]
RXF 393	IC₅₀	5.12 μM Compound: 1e	Cytotoxicity against human RXF 393 cells assessed as cell growth inhibition Cytotoxicity against human RXF 393 cells assessed as cell growth inhibition	[PMID: 36470105]
SF-268	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human SF-268 cells assessed as cell growth inhibition Cytotoxicity against human SF-268 cells assessed as cell growth inhibition	[PMID: 36470105]
SF-295	IC₅₀	8.27 μM Compound: 1e	Cytotoxicity against human SF-295 cells assessed as cell growth inhibition Cytotoxicity against human SF-295 cells assessed as cell growth inhibition	[PMID: 36470105]
SF-539	IC₅₀	0.96 μM Compound: 1e	Cytotoxicity against human SF-539 cells assessed as cell growth inhibition Cytotoxicity against human SF-539 cells assessed as cell growth inhibition	[PMID: 36470105]
SK-MEL-2	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human SK-MEL-2 cells assessed as cell growth inhibition Cytotoxicity against human SK-MEL-2 cells assessed as cell growth inhibition	[PMID: 36470105]
SK-MEL-28	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition	[PMID: 36470105]
SK-MEL-5	IC₅₀	3.12 μM Compound: 1e	Cytotoxicity against human SK-MEL-5 cells assessed as cell growth inhibition Cytotoxicity against human SK-MEL-5 cells assessed as cell growth inhibition	[PMID: 36470105]
SK-OV-3	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human SK-OV-3 cells assessed as cell growth inhibition Cytotoxicity against human SK-OV-3 cells assessed as cell growth inhibition	[PMID: 36470105]
SN12C	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human SN12C cells assessed as cell growth inhibition Cytotoxicity against human SN12C cells assessed as cell growth inhibition	[PMID: 36470105]
SNB-19	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human SNB-19 cells assessed as cell growth inhibition Cytotoxicity against human SNB-19 cells assessed as cell growth inhibition	[PMID: 36470105]
SNB-75	IC₅₀	7.16 μM Compound: 1e	Cytotoxicity against human SNB-75 cells assessed as cell growth inhibition Cytotoxicity against human SNB-75 cells assessed as cell growth inhibition	[PMID: 36470105]
SR	IC₅₀	0.58 μM Compound: 1e	Cytotoxicity against human SR cells assessed as cell growth inhibition Cytotoxicity against human SR cells assessed as cell growth inhibition	[PMID: 36470105]
SW-620	IC₅₀	1.97 μM Compound: 1e	Cytotoxicity against human SW620 cells assessed as cell growth inhibition Cytotoxicity against human SW620 cells assessed as cell growth inhibition	[PMID: 36470105]
T47D	IC₅₀	3.57 μM Compound: 1e	Cytotoxicity against human T47D cells assessed as cell growth inhibition Cytotoxicity against human T47D cells assessed as cell growth inhibition	[PMID: 36470105]
TK-10	IC₅₀	> 100 μM Compound: 1e	Cytotoxicity against human TK-10 cells assessed as cell growth inhibition Cytotoxicity against human TK-10 cells assessed as cell growth inhibition	[PMID: 36470105]
U-251	IC₅₀	4.81 μM Compound: 1e	Cytotoxicity against human U-251 cells assessed as cell growth inhibition Cytotoxicity against human U-251 cells assessed as cell growth inhibition	[PMID: 36470105]
UACC-257	IC₅₀	13.5 μM Compound: 1e	Cytotoxicity against human UACC-257 cells assessed as cell growth inhibition Cytotoxicity against human UACC-257 cells assessed as cell growth inhibition	[PMID: 36470105]
UACC-62	IC₅₀	6.47 μM Compound: 1e	Cytotoxicity against human UACC-62 cells assessed as cell growth inhibition Cytotoxicity against human UACC-62 cells assessed as cell growth inhibition	[PMID: 36470105]
UO-31	IC₅₀	18.7 μM Compound: 1e	Cytotoxicity against human UO-31 cells assessed as cell growth inhibition Cytotoxicity against human UO-31 cells assessed as cell growth inhibition	[PMID: 36470105]

In Vitro

Enpp/Carbonic anhydrase-IN-1 (compound 1e) (0-100 µM; ) inhibits some cancer cells growth with IC₅₀s of 0.32, 0.40, 0.58, 0.87, 0.40, 0.96 µM for K-562, RPMI-8226, SR, COLO 205, HT-29, SF-539 cells, respectively^[1].
Enpp/Carbonic anhydrase-IN-1 (0-2 µM) shows low cytotoxic against normal breast epithelial cells (HME1) and normal skin fibroblast cells (F180) with IC₅₀s of > 50 μM^[1].
Enpp/Carbonic anhydrase-IN-1 (0.32, 0.64 µM) induces apoptosis in a dose-dependent manner at K-562 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	K-562, RPMI-8226, SR, COLO 205, HT-29, SF-539 cells
Concentration:	0-100 µM
Incubation Time:
Result:	Inhibited the cell growth with IC₅₀s of 0.32, 0.40, 0.58, 0.87, 0.40, 0.96 µM for K-562, RPMI-8226, SR, COLO 205, HT-29, SF-539 cells, respectively.

Apoptosis Analysis^[1]

Cell Line:	K-562 cells
Concentration:	0.32, 0.64 µM
Incubation Time:
Result:	Induced apoptosis in a dose-dependent manner.

Molecular Weight

411.51

Formula

C₂₃H₂₅NO₄S

CAS No.

2883495-35-8

Appearance

Solid

Color

White to light yellow

SMILES

O=S(C1=CC=CC=C1)(OC2=CC=C(C=C2)NC(C34CC5CC(C4)CC(C3)C5)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (243.01 mM; ultrasonic and warming and heat to 50°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4301 mL	12.1504 mL	24.3007 mL
5 mM	0.4860 mL	2.4301 mL	4.8601 mL
10 mM	0.2430 mL	1.2150 mL	2.4301 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: 2.5 mg/mL (6.08 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.57%

Select Batch:

Data Sheet (276 KB) SDS (251 KB)

COA (254 KB) HNMR (260 KB) LCMS (266 KB)

Handling Instructions (2659 KB)

References

[1]. Afnan I.Shahin, et al. Design and synthesis of new adamantyl derivatives as promising antiproliferative agents. European Journal of Medicinal Chemistry, 2022.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4301 mL	12.1504 mL	24.3007 mL	60.7519 mL
	5 mM	0.4860 mL	2.4301 mL	4.8601 mL	12.1504 mL
	10 mM	0.2430 mL	1.2150 mL	2.4301 mL	6.0752 mL
	15 mM	0.1620 mL	0.8100 mL	1.6200 mL	4.0501 mL
	20 mM	0.1215 mL	0.6075 mL	1.2150 mL	3.0376 mL
	25 mM	0.0972 mL	0.4860 mL	0.9720 mL	2.4301 mL
	30 mM	0.0810 mL	0.4050 mL	0.8100 mL	2.0251 mL
	40 mM	0.0608 mL	0.3038 mL	0.6075 mL	1.5188 mL
	50 mM	0.0486 mL	0.2430 mL	0.4860 mL	1.2150 mL
	60 mM	0.0405 mL	0.2025 mL	0.4050 mL	1.0125 mL
	80 mM	0.0304 mL	0.1519 mL	0.3038 mL	0.7594 mL
	100 mM	0.0243 mL	0.1215 mL	0.2430 mL	0.6075 mL